FB825

FB825 is Oneness Biotech's humanized antibody designed to kill the B cells that are about to make IgE - the antibody class that drives allergic asthma, atopic dermatitis (AD), and hay fever. Two Phase 2 trials are recruiting: moderate-to-severe allergic asthma (NCT05008965, n=100) [1] and moderate-to-severe AD (NCT06397911, n=90, subcutaneous repeat-dose) [2], a combined enrollment of 190 patients. If the mechanism works as the biology predicts, FB825 could offer longer-lasting IgE suppression than Xolair (omalizumab) by depleting the source rather than mopping up the product. Whether that translates into fewer asthma attacks or clearer skin is exactly what these trials are built to find out, and the answer matters because anti-IgE has a mixed track record of mechanism-led improvements failing to beat first-generation drugs.

Novel biologic, never approved anywhere. FB825 originated at Fountain Biopharma and is now run by Oneness Biotech, a Taiwan-listed company (TWO: 4743) [5]. The drug has cleared Phase 1 in healthy volunteers (NCT02309762, n=54, single IV dose escalation 0.003-10 mg/kg) [3] and two small Phase 2 atopic dermatitis studies that were proof-of-mechanism rather than key: NCT03758716 (open-label, n=12) [4] and NCT05059509 (n=20, completed) [6]. A separate SC bridging PK Phase 1 study (NCT05952986) tested 300 mg and 450 mg single SC doses, supporting the SC route now used in the active Phase 2 AD trial [12]. The current active program is two larger Phase 2 placebo-controlled studies - one in allergic asthma reading exacerbations at 24 weeks [1], one in AD reading EASI percent change [2]. No FDA breakthrough therapy, fast track, orphan, or RMAT designations are on public record. The asthma trial's 24-week primary endpoint combined with currently recruiting status puts a credible readout no sooner than late 2027. No NDA or BLA filings exist. There is no Western pharma partner yet, which matters because Oneness lacks commercial infrastructure outside Taiwan and would need a licensee to compete in US and EU markets.

Allergic disease runs on IgE. When you encounter pollen, dust mite, or a food allergen, IgE coats mast cells and basophils, and the next exposure triggers those cells to dump histamine and inflammatory mediators - wheezing, hives, itch, anaphylaxis. Xolair (omalizumab) works by binding free IgE in circulation before it can stick to mast cells [7]. The catch: it does nothing to the B cells producing IgE, so when you stop dosing, IgE returns. FB825 attacks the source. Every B cell committed to making IgE displays IgE on its surface, anchored by a short extra peptide called CεmX that exists only on membrane IgE, not on the secreted form Xolair targets [8]. By binding CεmX, FB825 marks IgE-producing B cells for destruction, most likely via ADCC (antibody-dependent cellular cytotoxicity, where natural killer cells destroy the antibody-coated B cell). The biology is clean and the target is specific - depleting only the very small fraction (<1%) of B cells that have committed to IgE rather than the entire B-cell compartment, the way rituximab does. The active Phase 2 AD trial uses subcutaneous administration on a repeat-dose schedule [2], consistent with the SC bridging work [12]; precise dosing interval and the duration of post-dose IgE suppression have not been published in a peer-reviewed paper, and the durability claim therefore rests on unpublished sponsor data.

The asthma trial (NCT05008965) randomizes 100 adults with moderate-to-severe allergic asthma against placebo, with primary endpoint of occurrence of an asthma exacerbation at week 24 [1]. Exacerbations are a clinically meaningful binary endpoint - preferable to lung function alone - but they are noisy in 100-patient studies, so only large treatment effects will reach statistical significance. The AD trial (NCT06397911) enrolls 90 adults, also placebo-controlled, with primary endpoint of percent change from baseline in Eczema Area and Severity Index (EASI), a standardized clinician-rated score that combines lesion area and severity across body regions [2]. EASI percent change is the standard regulatory endpoint for AD and the same one Dupixent used. Both trials are sponsored by Oneness Biotech and were listed as recruiting as of the most recent updates. Neither includes an active comparator arm, so investors will get drug-versus-placebo numbers but no direct read against Xolair, Dupixent, or tezepelumab. That is defensible for a Phase 2 efficacy signal but limits the strategic value of the data - a positive trial justifies Phase 3, a clean miss likely kills the asthma program given how well dupilumab (FDA-approved for type 2/eosinophilic moderate-to-severe asthma as add-on maintenance) and tezepelumab already perform [11].

Our model estimates a 6% chance this drug is eventually approved. That figure starts from the historical base rate for drugs at this stage - about 30% - then adjusts based on ten specific facts about the trial and sponsor. The biggest drags on the estimate are heavier-than-usual blinding, the sponsor's thin or weak approval record, weak earlier-phase results, and a randomized trial design. The remaining factors fall close to average for this stage, so they leave the number roughly where the base rate put it.

Efficacy risk is the dominant concern. Ligelizumab demonstrated that deeper IgE suppression does not automatically beat first-generation anti-IgE on clinical endpoints - IgE level is a biomarker, not the actual disease driver in most patients [10]. Dupilumab's blockbuster success at IL-4Rα suggests the rate-limiting biology in AD sits upstream of IgE entirely [11]. Safety risk: depleting IgE-committed B cells via ADCC carries theoretical infection risk, though milder than rituximab's broad B-cell wipeout because the target population is tiny. Two distinct anaphylaxis considerations apply: (1) Xolair carries a black box for post-administration anaphylaxis observed in a small subset of patients after dosing [7], a class flag for any IgE-pathway biologic; and (2) FB825 has a separate, mechanism-specific concern - engaging membrane IgE on B cells could in principle crosslink IgE on adjacent mast cells or basophils, and the program must demonstrate the antibody does not trigger that activation. Execution risk: enrollment in moderate-to-severe AD is competitive with dupilumab, tralokinumab, lebrikizumab, abrocitinib, and upadacitinib all chasing the same patients [11]. Commercial risk: Dupixent generated approximately $14B in 2024 and Sanofi/Regeneron own AD prescribing habits [11]; FB825 needs a clear differentiation story - durability, dose frequency, cost - to take share. Oneness is small and Taiwan-based; without a Western partner, commercial reach is limited even with positive data.

Worth watching at low priority. The mechanism is biologically interesting - depleting antibody-producing cells rather than the antibodies themselves is a real differentiator on durability if it holds up, and early human data are reported to show the drug hits its target as expected, though peer-reviewed confirmation is missing [3][6]. Two things temper enthusiasm. First, anti-IgE has been a graveyard for mechanism-led improvements: ligelizumab was more potent and still lost to omalizumab in the Phase 3 PEARL program in CSU [10]. Second, dupilumab's dominance in AD and the strength of tezepelumab and dupilumab in severe asthma raise the bar for what a Phase 2 readout needs to look like to justify Phase 3 investment. The cleanest near-term signal is full publication of NCT05059509 results [6] - that is the first peer-reviewed read on whether IgE B-cell depletion translates to AD skin clearance. The larger trials are unlikely to deliver primary results before late 2027 on current recruiting pace [1][2]. The single most informative event would be a licensing deal with a major pharma; a Sanofi, Roche, or Novartis option would be the strongest commercial validation possible and would also de-risk Oneness's commercialization gap. Until then, this is a science-interesting, commercially uncertain Phase 2 asset.

Oneness Biotech (TWO: 4743) is a Taiwan-listed specialty biopharmaceutical company that acquired FB825 from Fountain Biopharma, originally developed in the lab of Tse-Wen Chang, who discovered the CεmX domain [8][5]. The company also markets Fespixon, a botanical wound-healing product in Taiwan, but has no globally approved drugs. FB825 is the lead pipeline asset and the company's principal value driver. Per the company's 2025 investor presentations, cash and realizable financial assets were approximately TWD 6.51 billion (roughly USD ~$200M at prevailing rates) as of Q3 2025, against an operating cash outflow of roughly TWD 0.43 billion in the period, which on the face of it provides multi-year runway to fund both active Phase 2 trials [5]. Investors should still verify the most recent quarterly figures independently. Oneness has no Western commercial infrastructure and no fully disclosed Western development partnership for FB825, which means a successful Phase 2 would almost certainly trigger a licensing process for US and EU rights. The market cap is modest by US biotech standards, and Phase 2 readout volatility will dominate the equity story. Investors tracking this should watch for any partnership disclosure, full peer-reviewed publication of completed Phase 2 data, and pace of enrollment in the two active trials as proxies for both clinical signal and management execution capacity.